After only one year as CEO and President of Sweden's Immunovia AB, Patrik Dahlen has informed the Board of Directors that he wishes to step down. The search for a successor has already begun. Dahlen will remain with the company for another six months.

Carl Borrebaeck, Chairman of the Board of Directors, commented:  “Immunovia’s mission is to detect and prevent pancreatic cancer, one of the deadliest cancer forms there is. Today, we stand stronger than ever with our pioneering IMMray™ PanCan-d test. Bringing us here has been a team effort, where Patrik has played a crucial role and achieved regulatory approval and launched the product, which is now available throughout the United States. We are now penetrating this prioritized market according to our strategy and will continue to do so with full focus. On behalf of the Board, I thank Patrik for this outstanding effort.”